Agile Therapeutics Stock News

PRINCETON, N.J., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the pricing of its underwritten public offering of 26,666,648

PRINCETON, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it intends to offer and sell shares of its common stock a

Largest Medicaid program in the U.S. adds Twirla to Preferred Drug List as of October 1, 2021 Largest Medicaid program in the U.S. adds Twirla to Preferred Drug List as of October 1, 2021

PRINCETON, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that management will present and participate at the followin

PRINCETON, N.J., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced a partnership with Pandia Health, an online telehealth servic

Agile Therapeutics recently reported their Q2 earnings with a beat on EPS and a miss on revenue. The company's flagship product, Twirla, is already starting to display impressive growth trends. The ma

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their ove

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their ove

Agile Therapeutics, Inc.'s (AGRX) CEO Al Altomari on Q2 2021 Results - Earnings Call Transcript

Shares of Agile Therapeutics (NASDAQ:AGRX) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 66.67% year over year to ($0.20), which beat th

Live Conference Call and Webcast at 4:30 p.m. EDT Live Conference Call and Webcast at 4:30 p.m. EDT

PRINCETON, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the company will be participating virtually in the William Blai

Agile Therapeutics: Returning To Bullish Outlook After Encouraging Q1 Earnings

Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q1 2021 Results - Earnings Call Transcript

Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 9.09% and -82.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?